Safety and efficacy of enalapril in multivalvular heart disease with significant mitral stenosis - SCOPE-MS

Angiology

Volumn 56, Issue 2, 2005, Pages 151-158

  Chockalingam, Anand ^a   Venkatesan, S ^a   Dorairajan, Smrita ^a   Chockalingam, V ^a   Subramaniam, T ^a   Jaganathan, V ^a   Elangovan, S ^a   Alagesan, R ^a   Gnanavelu, G ^a   Arul, A S ^a  

^a MADRAS MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; PULMONARY HYPERTENSION; RHEUMATIC HEART DISEASE; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE INSUFFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENALAPRIL; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART VALVE DISEASES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE STENOSIS; PROSPECTIVE STUDIES; RHEUMATIC HEART DISEASE; TREATMENT OUTCOME;

EID: 20144366194     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600205     Document Type: Article

References (27)

1. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Study Group. N Engl J Med 316:1429-1435, 1987.
2. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992.
3. Swedberg K, Held P, Kjekshus J, et al, on behalf of the CONSENSUS II Study Group: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678-684, 1992.
4. Litwin SE, Katz SE, Weinberg EO, et al: Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy: Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 91:2642-2654, 1995.
5. Morgan HE, Baker KM: Cardiac hypertrophy: Mechanical, neural, and endocrine dependence. Circulation 83:13-25, 1991.
6. Johnson W, Omland T, Hall C, et al: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39:1623-1629, 2002.
7. Schunkert H, Dzau VJ, Tang SS, et al: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload hypertrophy: Effects on coronary resistance, contractility, and relaxation. J Clin Invest 86:1913-1920, 1990.
8. Levine HJ, Gaasch WH: Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol. 28:1083-1091, 1996.
9. Schon HR, Dorn R, Barthel P, et al: Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis 3:500-509, 1994.
10. Schon HR: Hemodynamic and morphologic changes after long-term angiotensin converting enzyme inhibition in patients with chronic valvular regurgitation. J Hypertens Suppl 12:S95-S104, 1994.
11. Schon HR, Schroter G, Barthel P, et al: Quinapril therapy in patients with chronic mitral regurgitation. J Heart Valve Dis 3:303-312, 1994.
12. Tischler MD, Rowan RN, LeWinter MM: Effect of enalapril therapy on left ventricular mass and volumes in asymptomatic chronic, severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 15:242-245, 1998.
13. Montiel-Trujillo A, Mahon NG, Greenberg BH, et al: Congestive heart failure as a consequence of valvular heart disease. In: Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management, ed. 2, ed. by Hosenpud JD, Greenberg BH. Philadelphia: Lippincott Williams and Wilkins, 2000, pp 325-342.
14. Hinchman DA, Otto CM: Valvular disease in the elderly. Cardiol Clin 17:137-158, 1999.
15. Carabello BA, Stewart WJ, Crawford FA: Aortic valve disease. In: Textbook of Cardiovascular Medicine, ed. by Topol EJ. Philadelphia: Lippincott-Raven, 1998, pp 533-555.
16. Baim DS, Grossman W, eds: Grossman's Cardiac Catheterization, Angiography, and Intervention, ed. 6. Philadelphia: Lippincott Williams and Wilkins, 2000, p 206.
17. Chockalingam A, Gnanavelu G, Elangovan S, et al: Clinical spectrum of chronic rheumatic heart disease in India. J Heart Valve Dis (In press).
18. Khot UN, Novaro GM, Popovic ZP, et al: Nitroprus-side in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348:1756-1763, 2003.
19. Bagirova GG, Batalina MV: Treatment of chronic heart failure in patients with mitral and aortic valve defects of rheumatic origin. Ter Arkh 72:63-66, 2000.
20. Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377-381, 1982.
21. Guyatt GH, Sullivan MJ, Thompson PJ, et al: The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132:919-923, 1985.
22. WHO Study Group: Rheumatic Fever and Rheumatic Heart Disease. WHO Technical Report Series No. 764. Geneva: World Health Organization, 1988.
23. Murray CJ, Lopez AD, eds: Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 200 Conditions. Global Burden of Disease and Injury Series, vol. 2. Cambridge, MA: Harvard School of Public Health, 1996, pp 132-140.
24. Padmavati S: Rheumatic fever and rheumatic heart disease in developing countries. Bull World Health Organ 56:543-550, 1978.
25. Ahmed A, Kiefe CI, Allman RM, et al: Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 50:1659-1666, 2002.
26. Pelouch V, Kolar F, Ost'adal B, et al: Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: Effect of enalapril. Cardiovasc Drugs Ther 11:177-185, 1997.
27. Mahajan SK, Sharma VK, Thakral S: Effect of enalapril on renal profile and right ventricular dimensions in chronic cor pulmonale. J Assoc Physicians India 44:323-324, 1996.